Families and hospitals already grappling with a national shortage of liquid albuterol could soon find the critical drug solution used to treat lung conditions such as asthma even harder to obtain. The shortage — which began last year — is expected to worsen after a major supplier shuttered manufacturing plants in late February. To read the full story.